HK Stock Market Move | CARSGEN-B (02171) rose nearly 4% again as the universal BCMA CAR-T product CT0596 was approved for clinical trials in China.

CARSGEN-B (02171) rose nearly 4%, and as of the time of reporting, it was up 3.9%, trading at HK$14.65, with a transaction volume of HK$26,376,600. In terms of news, on August 4th, Keji Pharmaceutical announced that its self-developed BCMA-targeted CAR-T cell product CT0596 has officially obtained clinical trial implicit approval from the National Medical Products Administration, intended for use in patients with relapsed/refractory multiple myeloma (R/R MM) who have undergone at least three lines of treatment, marking the product's entry into the registered clinical development stage. Public information shows that CT0596 had previously been involved in investigator-initiated clinical studies in populations with relapsed/refractory multiple myeloma and plasma cell leukemia, and relevant positive data were presented as a poster at the 2026 European Hematology Association (EHA) annual meeting. This IND approval represents a critical milestone for the product's transition from early clinical exploration to standardized registered development.